BIO vs QGEN
BIO: A multinational life science and clinical diagnostics company providing research tools, diagnostic test systems, and consumables to laboratories and biopharmaceutical manufacturers worldwide. QGEN: QIAGEN supplies essential molecular diagnostic and sample preparation tools that enable laboratories and clinicians to detect, analyze, and validate genetic material and biomarkers.
Side-by-side fundamentals
| Metric | BIO | QGEN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $305.96 | $40.57 | |
| Market cap as of 2026-07-23 | $8.2B | $8.4B | |
| P/E as of 2026-07-23 | 48.82 | 20.77 | QGEN lower |
| PEG as of 2026-07-23 | n/a | 3.13 | |
| Net margin as of 2026-07-23 | +6.5% | +19.2% | QGEN higher |
| Gross margin as of 2026-07-23 | +51.8% | +62.6% | QGEN higher |
| Operating margin as of 2026-07-23 | +2.0% | +20.7% | QGEN higher |
| ROE as of 2026-07-23 | +2.4% | +11.3% | QGEN higher |
| ROA as of 2026-07-23 | +1.7% | +6.6% | QGEN higher |
| Debt / equity as of 2026-07-23 | 0.18 | 0.49 | BIO lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.9% | +4.8% | QGEN higher |
| Revenue CAGR (3y) SEC XBRL | -2.7% | n/a | |
| Dividend yield as of 2026-07-23 | n/a | +0.6% | |
| Beta as of 2026-07-23 | 1.06 | 0.63 | |
| 1-year return as of 2026-07-22 close | +24.6% | -18.1% | BIO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.